Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV LID ΔM2-2 Vaccine in Children
NCT02040831Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2014
- Primary completion
- Apr 2015
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in respiratory syncytial virus infection (RSV) comparing RSV LID ΔM2-2 Vaccine with Placebo Vaccine (2 arms). Primary endpoints: Frequency of vaccine-related solicited adverse events at Day 28, Proportion of participants with 4-fold or greater rise in RSV neutralizing antibody titer at Day 56 and 1 more. Started Sep 2014; status: completed.
02
Drugs
respiratory syncytial virus LID delta M2-2
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02040831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02040831.